Moreover, GSK3β inhibitors have been proposed as therapeutic agents for AD (Hooper et al., 2008; Medina & Castro, 2008) since it has been demonstrated that GSK3β inhibition reduces tau phosphorylation (Hooper et al., 2008; Medina & Castro, 2008) and even amyloid production, both in vitro and in vivo (Hooper et al., 2008; Su et al., 2004). Here, GSK3B is linked to Alzheimer disease.